Key Facts
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
We employ around 51,700 people (46% in Europe, 28% in the Americas and 26.5% in Asia-Pacific).
Latest press releases
- AstraZeneca Issues Update on Accelerated Oncology Pipeline in Advance of 2013 ASCO Annual Meeting
- 16 May 2013
- Taskforce meets to begin planning for future of Alderley Park
- 29 April 2013
- AstraZeneca PLC first quarter results 2013
- 25 April 2013
- AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine
- 22 April 2013
- AstraZeneca announces top-line results from OSKIRA-1 Phase III study of fostamatinib in rheumatoid arthritis
- 5 April 2013
- MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma
- 3 April 2013
- US District Court rules one PULMICORT RESPULES® (Budesonide Inhalation Suspension) patent invalid and another patent not infringed
- 2 April 2013
- AstraZeneca settles litigation over CRESTOR patent
- 25 March 2013
- AstraZeneca appoints Marc Dunoyer as Executive Vice President, Global Portfolio & Product Strategy
- 21 March 2013